Massachusetts-based AI biotechnology company Dewpoint Therapeutics has entered a research and development partnership with pharmaceutical manufacturing company Novo Nordisk to utilize Dewpoint's drug discovery platform in identifying potential drug candidates for the treatment of insulin resistant and diabetic complications.
The partnership aims to identify potential small molecule drugs against new condensate targets that might play a role in insulin resistance, a primary cause of type 2 diabetes and metabolic syndrome. Novo Nordisk may also utilize its internal capabilities to explore non-small molecule drugs with identified condensates as potential targets.
Under the terms of the partnership, Dewpoint will receive USD 55 million in near-term payments, which includes an initial payment, funds for research, and potential milestones for two programs. Additionally, Dewpoint is also able to make up to USD 690 million based on further clinical and commercial milestones, as well as royalties for two products.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.